What is the 13F Pro Quality Score for VERA?

13F Pro ranks Vera Therapeutics, Inc. (VERA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VERA's current score at https://13fpro.ai/research/VERA (free sign-up required for the full ranking).

Which hedge funds own the most VERA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VERA include Avoro Capital Advisors, BlackRock,, Deep Track Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/VERA as soon as new 13F filings post.

Where does 13F Pro source VERA data?

All Vera Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Vera Therapeutics, Inc. files with the SEC under CIK 1831828. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VERA in?

Vera Therapeutics, Inc. (VERA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VERA research updated on 13F Pro?

VERA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Vera Therapeutics, Inc.(VERA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1831828 VERA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

VERA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Vera Therapeutics, Inc. (VERA), a Healthcare sector company. VERA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Vera Therapeutics, Inc. reports net income of $-121.0M, free cash flow of $-106.5M. Top institutional holders of VERA by reported 13-F value include Avoro Capital Advisors, BlackRock,, Deep Track Capital,, based on the most recent SEC filings. VERA trades on the Nasdaq exchange and files with the SEC under CIK 1831828. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VERA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vera Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-121.0M

Free Cash Flow

Q1 2026

$-106.5M

D/E Ratio

Q1 2026

0.15

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-58.5% YoY

$-152.1MFY 2024

FY21 $-32.6MFY22 $-89.1MFY23 $-96.0MFY24 $-152.1M

Operating Income

-63.9% YoY

$-167.2MFY 2024

FY21 $-34.4MFY22 $-90.9MFY23 $-102.0MFY24 $-167.2M

EPS (Diluted)

-22.2% YoY

$-2.75FY 2024

FY21 $-2.43FY22 $-3.35FY23 $-2.25FY24 $-2.75

Total Assets

+273.5% YoY

$655.7MFY 2024

FY21 $83.7MFY22 $131.4MFY23 $175.5MFY24 $655.7M

Total Debt

+1.6% YoY

$50.7MFY 2024

FY21 $4.9MFY22 $24.8MFY23 $49.9MFY24 $50.7M

Op. Cash Flow

-46.1% YoY

$-134.7MFY 2024

FY21 $-23.7MFY22 $-67.6MFY23 $-92.2MFY24 $-134.7M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Net Income	$-152.1M -58.5%	$-96.0M -7.8%	$-89.1M -173.1%	$-32.6M	—
Operating Income	$-167.2M -63.9%	$-102.0M -12.2%	$-90.9M -164.2%	$-34.4M	—
EPS (Diluted)	$-2.75 -22.2%	$-2.25 +32.8%	$-3.35 -37.9%	$-2.43	—
Total Assets	$655.7M +273.5%	$175.5M +33.6%	$131.4M +56.9%	$83.7M	—
Total Debt	$50.7M +1.6%	$49.9M +101.0%	$24.8M +404.0%	$4.9M	—
Operating Cash Flow	$-134.7M -46.1%	$-92.2M -36.4%	$-67.6M -185.1%	$-23.7M	—

AI Insight: VERA Financial Trends

Vera Therapeutics remains pre-revenue with quarterly cash burn accelerating sharply to $106M in Q1 2026, up from $25M in Q2 2024.

• Operating cash outflow surged from $-25M in Q2 2024 to $-106M in Q1 2026, a more than fourfold increase in burn rate.

• Net loss widened from $-34M in Q2 2024 to $-121M in Q1 2026, reflecting escalating R&D and operating spend with zero revenue.

• Total debt rose modestly from $50M in Q2 2024 to $75M in Q2 2025 and held flat through Q1 2026, limiting leverage-driven risk so far.

• Equity jumped to $605M in Q4 2025 before declining to $500M in Q1 2026, suggesting equity raises partially offset accumulated losses.

⚠ Q1 2026 operating cash burn of $-106M is the highest on record; runway erosion could force additional dilutive equity raises near-term.

⚠ Equity fell $105M in a single quarter (Q4 2025 to Q1 2026) against flat debt — monitor whether the balance sheet can sustain this trajectory.

⚠ No revenue has appeared in any reported quarter; first commercial milestone or partnership deal would be a critical inflection to watch.

AI Insight: VERA Ratio Trends

VERA's return metrics are deteriorating sharply, with ROE hitting -96.9% and ROIC -87.1% in Q1 2026 — the worst readings in the dataset.

• ROE worsened from -30.1% in Q4 2024 to -96.9% in Q1 2026, signaling accelerating cash burn relative to equity.

• ROIC deepened from -31.2% in Q4 2024 to -87.1% in Q1 2026, the most negative level across all periods shown.

• D/E ratio has remained low and range-bound between 0.09 and 0.19, suggesting minimal debt-financing risk so far.

⚠ ROA fell to -77.9% in Q1 2026 from -26.5% in Q4 2024 — asset productivity is deteriorating at an accelerating pace.

⚠ D/E ticked back up to 0.15 in Q1 2026 after reaching a low of 0.09 in Q4 2024 — watch for further leverage creep.

Get alerted when VERA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vera Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VERA

Avoro Capital Advisors LLC
$236.9M5,888,888 sh
BlackRock, Inc.
$204.7M5,088,102 sh
Deep Track Capital, LP
$165.2M4,106,067 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$149.7M3,722,100 sh
Kynam Capital Management, LP
$136.7M3,398,224 sh
STATE STREET CORP
$135.3M3,363,638 sh
Sofinnova Ventures Inc
$112.4M2,793,987 sh
VANGUARD CAPITAL MANAGEMENT LLC
$108.0M2,683,607 sh
FMR LLC
$107.7M2,676,422 sh
Eversept Partners, LP
$87.4M2,173,286 sh

Fund	Value	Shares
Avoro Capital Advisors LLC	$236.9M	5,888,888
BlackRock, Inc.	$204.7M	5,088,102
Deep Track Capital, LP	$165.2M	4,106,067
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$149.7M	3,722,100
Kynam Capital Management, LP	$136.7M	3,398,224
STATE STREET CORP	$135.3M	3,363,638
Sofinnova Ventures Inc	$112.4M	2,793,987
VANGUARD CAPITAL MANAGEMENT LLC	$108.0M	2,683,607
FMR LLC	$107.7M	2,676,422
Eversept Partners, LP	$87.4M	2,173,286

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VERA on your watchlist

Track score changes the day Vera Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VERA a good stock to buy?

13F Pro's AI-powered analysis of Vera Therapeutics, Inc. (VERA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VERA are available on the VERA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VERA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VERA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vera Therapeutics, Inc.'s investment landscape.